{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of March 2023): No"],"condition":["Lymphoma, Large B-Cell, Diffuse","Lymphoma, T-Cell","Carcinoma","Triple Negative Breast Neoplasms","Carcinoma, Non-Small-Cell Lung","Hodgkin Disease","Lymphoma, T-Cell, Peripheral","Colorectal Cancer","Non Small Cell Lung Cancer","Triple Negative Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Breast Neoplasms","Cutaneous Squamous Cell Carcinoma","Lymphoma, B-Cell","Small Bowel Cancer","Hodgkin Lymphoma","Squamous Cell Carcinoma of Head and Neck","Esophageal Neoplasms","Colorectal Neoplasms","Solid Tumor","Diffuse Large B Cell Lymphoma","Burkitt Lymphoma","Lymphoma","Diffuse large B-cell lymphoma","Carcinoma, Squamous Cell","Head and Neck Squamous Cell Carcinoma","T-cell Lymphoma","Esophageal Cancer"],"disease":["Lymphoma, Large B-cell, Diffuse","Carcinoma","Triple Negative Breast Neoplasms","Hodgkin Disease","Colorectal Cancer","Non Small Cell Lung Cancer","Triple Negative Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Breast Neoplasms","Cutaneous Squamous Cell Carcinoma","Small Bowel Cancer","Hodgkin Lymphoma","Esophageal Neoplasms","Colorectal Neoplasms","Carcinoma, Non-small-cell Lung","Head And Neck Squamous Cell Carcinoma","Lymphoma, T-cell","Lymphoma, T-cell, Peripheral","Solid Tumor","Diffuse Large B Cell Lymphoma","Burkitt Lymphoma","Diffuse Large B-cell Lymphoma","Lymphoma","Carcinoma, Squamous Cell","Squamous Cell Carcinoma Of Head And Neck","T-cell Lymphoma","Esophageal Cancer","Lymphoma, B-cell"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2750284"],"location":["United States"],"study_start_month":["11"],"keyword":["CD161","Hormone receptor positive breast cancer","Small bowel carcinoma"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","description":"This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas.\nThe main goals of this study are to:\n* Find the recommended dose of IMT-009 that can be safely given to participants\n* Learn more about the side effects of IMT-009\n* Learn more about pharmacokinetics of IMT-009\n* Learn more about the effectiveness of IMT-009\n* Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009","dates":{"creation":"2022-11-15"},"accession":"2750284","cross_references":{"ClinicalTrials___gov":["NCT05565417"]}}